ENDOCYTE INC Business Operations Contracts & Agreements

32 Contracts & Agreements
Browse by Subcategory
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Global Supply Agreement, dated as of July 5, 2018, between Endocyte, Inc. and ITG Isotope Technologies Garching GmbH
Supply Agreements
ENDOCYTE INC
IN
2018
COLLABORATION, EXCLUSIVE LICENSE, AND COMPANION DIAGNOSTIC AGREEMENT by and between Merck Sharp & Dohme Research GmbHand ENDOCYTE, INC.
Collaboration Agreements
ENDOCYTE INC
NY
2012
Obtain marketing approval of our phase 3-ready SMDC, EC145, for use in women with platinum-resistant ovarian cancer. We plan to initiate a randomized, controlled, double-blinded...
Marketing Agreements
ENDOCYTE INC
2011
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2011
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2011
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
DE
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
MD
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
NY
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
DE
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010